The Abbott baby formula contamination recall, initiated in February 2022, represents one of the most significant product safety incidents affecting infants in recent years. The recall involved Similac, Alimentum, and EleCare powdered infant formulas manufactured at Abbott’s Sturgis, Michigan facility, which were contaminated with dangerous bacteria including Cronobacter sakazakii and Salmonella Newport. At the center of this crisis were four documented cases of infant infection and two confirmed deaths from Cronobacter contamination, prompting immediate FDA intervention and triggering multiple class action lawsuits that continue through 2026.
The contamination incident exposed systemic failures in facility sanitation and quality control at one of America’s largest infant formula manufacturers. An FDA inspection revealed “egregiously unsanitary” conditions including bacteria found in non-product contact areas, cracks in equipment, roof leaks, standing water, and inadequate handwashing procedures—conditions that should never exist in a food facility, let alone one producing formula for vulnerable infants. Families who purchased these products during the recall period, whether their children became ill or not, have pursued legal compensation for medical expenses, pain and suffering, and economic losses.
Table of Contents
- What Triggered the Abbott Formula Recall and When Did It Happen?
- What Bacteria Contaminated the Abbott Formula and What Were the Health Effects?
- What Did the FDA Find During Its Inspection of the Sturgis Plant?
- What Class Action Litigation Has Been Filed Against Abbott?
- Who Can File a Claim in the Abbott Baby Formula Class Action?
- What Is the Current Status of Abbott’s Sturgis Plant and Ongoing Oversight?
- What Does the Future Hold for Abbott Litigation and Infant Formula Safety?
- Conclusion
What Triggered the Abbott Formula Recall and When Did It Happen?
Abbott voluntarily recalled powdered infant formulas on February 2, 2022, after the company received four consumer complaints involving infants who consumed contaminated powder formula. The recall affected three major product lines under the Abbott brand—Similac, Alimentum (for sensitive digestion), and EleCare (for hypoallergenic needs)—all manufactured at the Sturgis plant. What made this recall particularly urgent was the speed with which health authorities connected contamination to severe illness in infants, leading to CDC and FDA investigations that identified Cronobacter sakazakii as the culprit bacteria.
The timing of this recall was especially consequential because it occurred during a period of already-tight infant formula supply in the United States. A single manufacturer’s facility closure created widespread shortages, affecting millions of families nationwide who relied on these specific formulas. Parents who had no alternative option were left scrambling to find compatible products, sometimes resorting to formula from other countries or mixing feeds in ways that weren’t medically recommended—a limitation of relying too heavily on one manufacturer for essential baby nutrition.
What Bacteria Contaminated the Abbott Formula and What Were the Health Effects?
Two bacterial pathogens contaminated the affected Abbott formulas: Cronobacter sakazakii and Salmonella Newport. Cronobacter is particularly dangerous for infants under three months old, as it can cause life-threatening infections including meningitis and bacteremia, which can progress rapidly. Salmonella Newport causes severe gastrointestinal illness and can lead to bloodstream infections, especially in infants whose immune systems are still developing.
The CDC documented four confirmed infant infections linked to contaminated Similac products, and tragically, two infants died from Cronobacter infection as of March 10, 2022. However, a critical caveat emerged during the investigation: FDA, CDC, and Abbott investigations, including genetic sequencing and retained product testing, did not find a definitive link between the company’s manufactured products and the reported illnesses in infants. This scientific finding became central to the ongoing litigation, as it raised questions about whether contamination occurred during manufacturing, distribution, or at home—and whether Abbott could be held liable if the connection between product and illness couldn’t be definitively proven. This uncertainty has made settlement negotiations complex and created a warning for other manufacturers: contamination can occur at multiple points in a supply chain, and proving causation in class actions involving infant formula is far more complicated than consumers might assume.
What Did the FDA Find During Its Inspection of the Sturgis Plant?
The FDA’s inspection of Abbott’s Sturgis, Michigan facility revealed conditions that shocked federal regulators and the public alike. The plant was described as “egregiously unsanitary,” with specific violations including bacteria detected in non-product contact areas (suggesting overall contamination risk), visible cracks in equipment, roof leaks allowing water intrusion, standing water pooling in the facility, and inadequate handwashing procedures that fell far below industry standards. These weren’t minor lapses—they represented fundamental failures in basic sanitation and food safety protocols.
The facility closure lasted several months, with the Sturgis plant resuming production in July 2022. However, the damage to Abbott’s manufacturing capacity proved long-lasting. By 2024, the plant was producing 41% less infant formula compared to 2021 levels—evidence that the recall had lasting operational and market impacts. For families, the warning here is clear: even when a manufacturer resumes operations and passes new inspections, recovery to previous production levels may take years, potentially affecting product availability and creating price pressures in the market.
What Class Action Litigation Has Been Filed Against Abbott?
Multiple class action lawsuits were filed in federal courts following the contamination recall, with over 750 Similac lawsuits documented as of 2024. These cases fall into two main categories: claims involving necrotizing enterocolitis (NEC), a serious bowel condition in premature infants, and economic loss claims from families who purchased the contaminated formula without experiencing illness. A federal bellwether case—a lawsuit selected to represent how juries might decide similar cases—was originally scheduled for trial but has been reset to July 6, 2026. A significant development occurred in July 2024 when a jury returned a verdict awarding $95 million in compensatory damages and $400 million in punitive damages in one trial.
This verdict signals that juries are willing to hold Abbott financially responsible, though the relationship between the contamination and the specific health outcomes alleged in each case remains contested. Judge Matthew F. Kennelly has appointed settlement special master Randi Ellis to facilitate resolution discussions, suggesting that rather than proceeding case-by-case through trial, there may be a structured settlement in the coming months. This comparison matters: some families may receive faster, guaranteed compensation through settlement rather than risking continued litigation with uncertain jury outcomes.
Who Can File a Claim in the Abbott Baby Formula Class Action?
Eligibility for Abbott formula class actions generally includes families who purchased Similac, Alimentum, or EleCare powdered infant formula manufactured at the Sturgis facility during the recall period (February 2022 and shortly thereafter), regardless of whether their infant became ill. Some cases focus on economic damages—the cost of purchasing contaminated formula that families can no longer trust—while others pursue compensation for medical expenses and pain and suffering if the child contracted a bacterial infection or condition like NEC. The key limitation here is timing and documentation.
Families typically need to provide proof of purchase (receipts, credit card statements) and, if claiming for illness, medical records showing infection or diagnosis during the relevant period. Because the deadline for filing in certain lawsuits may have already passed or be approaching, families should act quickly to consult with a class action administrator or attorney to understand their eligibility and any remaining claim filing deadlines. The window to recover compensation doesn’t stay open indefinitely, and missing deadlines can permanently forfeit a family’s right to participate.
What Is the Current Status of Abbott’s Sturgis Plant and Ongoing Oversight?
Abbott continues to operate the Sturgis facility under enhanced FDA oversight with strict compliance measures designed to prevent future contamination. The company implemented new sanitation protocols, upgraded equipment, and increased quality testing following the facility’s reopening in July 2022. Regular FDA inspections and monitoring have resumed, and the public health agencies maintain active surveillance of Abbott’s infant formula products.
Despite these measures, trust hasn’t fully recovered. The company’s production capacity remains significantly below pre-recall levels—producing 41% less formula in 2024 than in 2021. Additionally, a DOJ investigation of the plant incident was documented in 2024, indicating that criminal or civil liability questions remain under government review. Families considering purchasing Abbott products should know that the company remains under heightened federal scrutiny, though current products undergo testing before distribution.
What Does the Future Hold for Abbott Litigation and Infant Formula Safety?
The federal bellwether cases scheduled for July 2026 will likely shape the final resolution of hundreds of pending Similac lawsuits. Settlement negotiations facilitated by Special Master Randi Ellis may result in a structured settlement fund that compensates eligible families without requiring individual trials. However, the absence of definitive proof linking Abbott’s manufactured product to the illnesses—despite the facility’s documented unsanitary conditions—means that settlements may be more modest than in cases where causation is clear.
Looking ahead, this incident has prompted broader discussions about infant formula manufacturing oversight, supply chain resilience, and the concentration of production among a small number of manufacturers. The FDA has increased scrutiny of infant formula plants nationwide, and Congress has examined whether regulatory standards adequately protect the most vulnerable consumers. For families navigating this period, the takeaway is that litigation may continue into 2026 and beyond, but the window to claim compensation is closing—action now is crucial.
Conclusion
The Abbott baby formula contamination recall represents a significant failure in food safety oversight with lasting legal and market consequences. While the FDA’s investigation didn’t establish definitive proof that Abbott’s products caused the documented illnesses, the company’s facility was found to have egregiously unsanitary conditions that endangered consumers.
Over 750 lawsuits remain pending, with federal courts working toward settlements that may provide compensation for affected families. If your family purchased Abbott powdered infant formulas manufactured at the Sturgis facility between February 2022 and mid-2022, or if your infant experienced illness potentially connected to this contamination, you may be eligible to file a claim. With litigation timelines extending into July 2026 and settlement discussions ongoing, the time to act is now—consult with a qualified attorney or class action administrator to understand your rights and file before claim deadlines expire.